QIAGEN/$QGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Ticker
$QGEN
Sector
Primary listing
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
5,700
ISIN
NL0015002CX3
Website
QIAGEN Metrics
BasicAdvanced
$10B
114.81
$0.42
0.68
$0.25
0.52%
Price and volume
Market cap
$10B
Beta
0.68
52-week high
$48.90
52-week low
$37.63
Average daily volume
1.4M
Dividend rate
$0.25
Financial strength
Current ratio
3.371
Quick ratio
2.523
Long term debt to equity
39.704
Total debt to equity
41.326
Interest coverage (TTM)
12.87%
Profitability
EBITDA (TTM)
703.035
Gross margin (TTM)
66.90%
Net profit margin (TTM)
4.68%
Operating margin (TTM)
26.25%
Effective tax rate (TTM)
32.32%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
5.76%
Return on equity (TTM)
2.67%
Valuation
Price to earnings (TTM)
114.815
Price to revenue (TTM)
5.217
Price to book
3.07
Price to tangible book (TTM)
15.63
Price to free cash flow (TTM)
20.769
Free cash flow yield (TTM)
4.81%
Free cash flow per share (TTM)
232.46%
Dividend yield (TTM)
0.52%
Forward dividend yield
0.52%
Growth
Revenue change (TTM)
3.31%
Earnings per share change (TTM)
-72.82%
3-year revenue growth (CAGR)
-4.68%
10-year revenue growth (CAGR)
4.21%
3-year earnings per share growth (CAGR)
-45.27%
10-year earnings per share growth (CAGR)
-1.86%
Bulls say / Bears say
QIAGEN reported a 5% year-over-year increase in net sales for Q3 2024, with Diagnostic solutions leading at 10% constant exchange rate growth, indicating strong demand for its products. (globenewswire.com)
The company has set a target of 7% annual sales growth until 2028, focusing on lab testing machines for infections and cancer, suggesting a clear growth strategy. (reuters.com)
QIAGEN's adjusted operating income margin improved to 29.6% in Q3 2024, up 3 percentage points from the previous year, reflecting enhanced profitability. (globenewswire.com)
QIAGEN's net sales declined by 5% in Q1 2024 compared to the same period in 2023, indicating potential challenges in maintaining revenue growth. (biospace.com)
The company reported a net loss per share of $0.83 in Q2 2024, despite adjusted diluted EPS of $0.55, suggesting underlying financial pressures. (globenewswire.com)
QIAGEN's total assets decreased from $6.29 billion in 2022 to $5.69 billion in 2024, which may raise concerns about asset management and financial stability. (qiagen.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
QIAGEN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for QIAGEN stock?
QIAGEN (QGEN) has a market cap of $10B as of July 15, 2025.
What is the P/E ratio for QIAGEN stock?
The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 114.81 as of July 15, 2025.
Does QIAGEN stock pay dividends?
Yes, the QIAGEN (QGEN) stock pays dividends to shareholders. As of July 15, 2025, the dividend rate is $0.25 and the yield is 0.52%. QIAGEN has a payout ratio of 0% on a trailing twelve-month basis.
When is the next QIAGEN dividend payment date?
The next QIAGEN (QGEN) dividend payment date is unconfirmed.
What is the beta indicator for QIAGEN?
QIAGEN (QGEN) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.